This research project is testing a new treatment for wet AMD. The treatment is called faricimab.

Vision loss associated with wet AMD is caused by the abnormal growth of new, leaky blood vessels at the back of the eye. To treat this, doctors often use a type of medication called anti-vascular endothelial growth factor (Anti-VEGF) that is injected into the affected eye on a set schedule.

Faricimab is one specific Anti-VEGF medication currently approved in Australia for the treatment of wet AMD and diabetic macular oedema, and is typically injected every 4 weeks for the first 4 doses.

The purpose of this study is to evaluate the effects, good or bad, of increasing the amount of time between each treatment of faricimab in patients with wet AMD. The study runs for approximately 2 years and would require participants to attend Cerulea on a monthly basis for study assessments and/or treatment appointments.
For further information about this study please contact the Clinical Trials Research Centre on (03) 9929 8076 or email info@ceruleaclinicaltrials.org.au